-+ 0.00%
-+ 0.00%
-+ 0.00%

PharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M

Benzinga·11/25/2025 14:19:23
Listen to the news

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's strategic approach to capital deployment and strengthening its already solid financial position.

Following the monetization of the stake, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Company's ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile.